Wednesday, June 15th, 2016 - WiseGuyReports

WiseGuyReports.com adds“Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) Therapeutics & Drugs Pipeline Review to 2016”reports to its database.

COMPLETE REPORT DETAILS @ https://www.wiseguyreports.com/reports/nicotinamide-phosphoribosyl-transferase-namprtase-or-pre-review-h1-2016

Summary

The ‘Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Pipeline Review, H1 2016’, provides in depth analysis on Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted pipeline therapeutics.

The report provides comprehensive information on the Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted therapeutics development and features dormant and discontinued projects.

The  report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

For more information or any query mail at [email protected]     

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) 
- The report reviews Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) 
- Identify the use of drugs for target identification and drug repurposing 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

REQUEST FOR SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/nicotinamide-phosphoribosyl-transferase-namprtase-or-pre-review-h1-2016

Companies Involved In This Report:

Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Companies Involved in Therapeutics Development
Angelini Group
Aurigene Discovery Technologies Limited  
Calico LLC
FORMA Therapeutics, Inc.
Genentech, Inc.
Karyopharm Therapeutics, Inc.
OncoTartis, Inc.

CONTINUE…….

CHECK DISCOUNT ON THIS REPORT @  https://www.wiseguyreports.com/check-discount/nicotinamide-phosphoribosyl-transferase-namprtase-or-pre-review-h1-2016

For more information or any query mail at [email protected]

Contact Profile

WiseGuyReports


Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

Our Market Research Reports and Consulting Services 

Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories. The Wise Guy Reports team prides itself in being the chosen source for market research reports, report customizations services, and other ancillary services such as a Newsletter service and corporate service for large organizations.

Hundreds of large and small organizations across virtually every industry sector worldwide are currently reaping rich dividends from the sharp insights provided by market research reports sourced through Wise Guy Reports. 

Gaining an insight into emerging trends, opportunities and potential threats is key to long-term sustenance in a competitive environment. The handpicked collection of market research reports on Wise Guy Reports is centred on this proven principle.


Norah Trent
P: +44 208 133 9349
M: +1 646 845 9349
W: www.wiseguyreports.com/

Keywords

Nicotinamide Phosphoribosyl Transferase,Nicotinamide Phosphoribosyl Transferase Industry,Nicotinamide Phosphoribosyl Transferase Market,Nicotinamide Phosphoribosyl Transferase Market Trend,Nicotinamide Phosphoribosyl Transferase Industry Trends,Nicotinami

Categories

Newsrooms

Sharing

More Formats